Trospium ER is an extended-release formulation of trospium chloride, a medication used to treat overactive bladder (OAB) [1]. OAB is a condition characterized by urinary urgency, with or without urinary incontinence, often accompanied by frequency and nocturia [2]. Trospium ER works by blocking muscarinic receptors in the bladder muscle, which helps to relax the bladder and increase its capacity [2][3].
How does trospium ER work to treat overactive bladder?
Trospium ER is an anticholinergic medication. It binds to muscarinic receptors, which are found on the smooth muscle cells of the bladder. By blocking these receptors, trospium ER inhibits the action of acetylcholine, a neurotransmitter that stimulates bladder muscle contractions. This results in decreased involuntary bladder contractions, leading to reduced urinary urgency, frequency, and incontinence associated with OAB [2][3].
When did trospium ER become available?
The extended-release formulation of trospium chloride, marketed as Sanctura XR, was approved by the U.S. Food and Drug Administration (FDA) in 2007 [4].
What are the potential side effects of trospium ER?
Common side effects of trospium ER can include dry mouth, constipation, urinary retention, blurred vision, and dizziness [2][5]. Patients with certain medical conditions, such as glaucoma, myasthenia gravis, or significant gastrointestinal or bladder obstructive disease, should use trospium ER with caution [2].
How does trospium ER compare to immediate-release trospium?
The extended-release formulation of trospium is designed to provide a more consistent drug level in the body throughout the day compared to the immediate-release version. This can potentially lead to fewer fluctuations in side effects and may allow for less frequent dosing [4]. Immediate-release trospium typically requires dosing two to three times a day, while extended-release trospium is usually taken once a day [3][4].
Are there other medications used for overactive bladder?
Yes, several other classes of medications are used to treat OAB, including other antimuscarinic agents like oxybutynin, tolterodine, and solifenacin, as well as beta-3 adrenergic agonists like mirabegron [6]. Treatment choices often depend on individual patient needs, response to therapy, and tolerance of side effects.
When does the patent for trospium ER expire?
Information on the specific patent expiration dates for trospium ER formulations can be found through specialized resources. DrugPatentWatch.com provides detailed patent information, including expiration timelines for various drug products [7].
What are the concerns regarding generic availability of trospium ER?
The availability of generic versions of trospium ER depends on patent exclusivity and any regulatory hurdles. Once patents expire and any market exclusivity periods conclude, generic manufacturers may seek FDA approval to market their own versions, potentially leading to lower costs for consumers [7].